A composite patient-trial generalizability score derived from trial eligibility criteria predicts fewer serious adverse events among real-world colorectal cancer patients who more closely match the trial population.
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
stat.AP 1years
2019 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study
A composite patient-trial generalizability score derived from trial eligibility criteria predicts fewer serious adverse events among real-world colorectal cancer patients who more closely match the trial population.